Respuesta a la carta al director referida a «Fibrilación auricular no valvular en pacientes en hemodiálisis crónica. ¿Debemos anticoagular?»

Sánchez-Gonzalez, Carmen; Herrero Calvo, José A.
Nefrología (Madrid) ; 43(1): 150-151, ene.-feb. 2023.
Artículo en Español | IBECS (España) | ID: ibc-215253

Documentos relacionados

  1. [Direct oral anticoagulants : therapeutic breakthroughs over the past decade].
  2. [Specific Features of the Course of Acute Coronary Syndrome in Patients with Newly Developed Atrial Fibrillation in Clinical Practice According to the Data of the Register of Acute Coronary Syndrome].
  3. Call me maybe? The right time and place for BPAs in EHRs.
  4. A treatment-specific marginal structural Cox model for the effect of treatment discontinuation.
  5. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.
  6. Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation.
  7. ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project.
  8. The link between atrial fibrillation and hereditary channelopathies: Authors' reply.
  9. Artificial intelligence and atrial fibrillation.
  10. Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin.